$1.38
7.81% day before yesterday
Nasdaq, Nov 28, 09:33 pm CET
ISIN
US03835L1089
Symbol
APVO

Aptevo Therapeutics Inc Stock price

$1.38
-0.08 5.48% 1M
-3.22 70.00% 6M
-84.82 98.40% YTD
-254.14 99.46% 1Y
-94,097.02 100.00% 3Y
-1,423,847.42 100.00% 5Y
-3,646,718.62 100.00% 10Y
-3,646,718.62 100.00% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.10 7.81%
ISIN
US03835L1089
Symbol
APVO
Industry

Key metrics

Basic
Market capitalization
$23.3m
Enterprise Value
$2.2m
Net debt
positive
Cash
$21.1m
Shares outstanding
13.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
30.5%
Return on Equity
-504.7%
ROCE
-124.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-26.5m | -
EBIT
$-26.7m | $-23.4m
Net Income
$-28.0m | $-199.7m
Free Cash Flow
$-26.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-9.4% | -
EBIT
-8.5% | 6.5%
Net Income
-17.8% | -732.3%
Free Cash Flow
-12.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-6.9
FCF per Share
$-1.9
Short interest
4.6%
Employees
37
Rev per Employee
$0.0
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
12% 12%
-
- Research and Development Expense 15 15
6% 6%
-
-26 -26
9% 9%
-
- Depreciation and Amortization 0.23 0.23
43% 43%
-
EBIT (Operating Income) EBIT -27 -27
9% 9%
-
Net Profit -28 -28
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
19 days ago
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company advancing differentiated immunotherapies, announced the first presentation of preclinical data for its new trispecific antib...
Neutral
Accesswire
23 days ago
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique use of the CRIS-7-derived CD3 binding domain, associated with favorable safety outcomes in the cli...
Neutral
Accesswire
about 2 months ago
SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial, industry, scientific and medical conferences this fall, providing the opportunity to highlight continu...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 37
Founded 2016
Website aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today